Walleye Capital
CRSP icon

Walleye Capital’s CRISPR Therapeutics CRSP Stock Holding History

Walleye Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.5K Buy
+915
New +$48.3K ﹤0.01% 3935
2025
Q3 		– Sell
-25,131
Closed -$1.44M – 4608
2025
Q2 		$1.22M Sell
25,131
-133,304
-84% -$5.16M ﹤0.01% 1890
2025
Q1 		$5.39M Buy
158,435
+142,908
+920% +$6.06M 0.02% 734
2024
Q4 		$611K Buy
15,527
+15,122
+3,734% +$714K ﹤0.01% 2828
2024
Q3 		$19K Sell
405
-331
-45% -$16.8K ﹤0.01% 4822
2024
Q2 		$39.8K Buy
736
+144
+24% +$8.33K ﹤0.01% 4989
2024
Q1 		$40.4K Buy
+592
New +$42.4K ﹤0.01% 4749
2023
Q1 		– Sell
-32,358
Closed -$1.57M – 3992
2022
Q4 		$1.32M Buy
+32,358
New +$1.72M 0.02% 819
2019
Q4 		– Sell
-1,555
Closed -$64K – 1874
2019
Q3 		$64K Buy
+1,555
New +$74.3K ﹤0.01% 1544

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Walleye Capital's CRSP Position: Q1 2026 in Review

Walleye Capital opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 915 shares worth $43.5K. The stake represents ﹤0.01% of the portfolio and ranks #3935 among its holdings. This is a return to the name: Walleye Capital previously reported a position in CRSP as recently as Q2 2025.

Walleye Capital first reported a position in CRSP in Q3 2019 and has held it in 9 quarters since. The position peaked at $5.39M in Q1 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Walleye Capital held 915 shares of CRISPR Therapeutics worth $43.5K as of Q1 2026.
  • CRISPR Therapeutics was a new Walleye Capital position in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3935 holding.
  • Walleye Capital first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 9 quarters since.
  • Walleye Capital's CRISPR Therapeutics position peaked at $5.39M in Q1 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.